Antipodean Pharmaceuticals Announces Completion Of Phase 2 Study Of Lead Compound MitoQ(R)
Apr 11th 2008Drug InformationClinical Trials
Antipodean Pharmaceuticals, Inc. announced that it has completed its Phase 2 study of its lead compound, MitoQ(R) (mitoquinone) in liver disease. The results of the study will be presented at The European Association for the Study of the Liver (EASL) Annual Meeting, being held April 23 - 27 in Milan, Italy. The poster, titled “Phase II Study of the Mitochondrial Antioxidant Mitoquinone for Hepatitis C,” will be presented April 24, 2008.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
